RT Journal Article
SR Electronic
T1 Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA1098
DO 10.1183/13993003.congress-2021.PA1098
VO 58
IS suppl 65
A1 Veiga Teijeiro, Iria
A1 Guzmán Peralta, Indhira
A1 Pérez De Llano, Luis
A1 Martín Robles, Irene
A1 Blanco Cid, Nagore
A1 Dacal Rivas, David
A1 Davila, Ignacio
A1 Martínez-Moragón, Eva
A1 Domínguez Ortega, Javier
A1 Almonacid, Carlos
A1 Colás, Carlos
A1 García-Rivero, Juan Luis
A1 Carmona, Loreto
A1 García De Yébenes, María Jesús
A1 García-Cosío, Borja
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA1098.abstract
AB Background: There is a lack of tools to holistically quantify the response to monoclonal antibodies (mAbs) in severe uncontrolled asthma (SUA) patients. The aim of this study was to develop a valid score to assist specialists in this clinical context.Methods: The score was developed in 4 subsequent phases: (1) elaboration of the theoretical model of the construct intended to be measured (response to mAbs); (2) definition and selection of items and measurement instruments by Delphi survey; (3) weight assignment of the selected items by multicriteria decision analysis (MCDA) using the Potentially All Pairwise RanKings of all possible Alternatives (PAPRIKA) methodology via the 1000Minds software; and (4) face validity assessment of the obtained score.Results: Four core items, with different levels of response for each of them, were selected: “severe exacerbations”, “oral corticosteroid use”, “symptoms” (evaluated by Asthma Control Test: ACT) and “bronchial obstruction” (assessed by FEV1% theoretical). “Severe exacerbations” and “oral corticosteroid maintenance dose” were weighted most heavily (38% each), followed by “symptoms” (13%) and “FEV1” (11%). Higher scores in the weighted system indicate better response and the range of responses runs from 0 (worsening) to 100 (best possible response). Face validity was high (intraclass correlation coefficient: 0.86).Conclusions: The FEOS score (FEV1, Exacerbations, Oral corticosteroids, Symptoms) allows clinicians to quantify response in SUA patients who are being treated with mAbs.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA1098.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).